Tyme Technologies Stock Price, News & Analysis (NASDAQ:TYME)

$3.43 -0.07 (-2.00 %)
(As of 02/21/2018 02:19 AM ET)
Previous Close$3.50
Today's Range$3.33 - $3.51
52-Week Range$2.14 - $9.50
Volume45,371 shs
Average Volume164,855 shs
Market Capitalization$318.16 million
P/E Ratio-20.59
Dividend YieldN/A
Beta-0.59

About Tyme Technologies (NASDAQ:TYME)

Tyme Technologies logoTyme Technologies, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. The Company’s lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and it is preparing to initiate an additional Phase II clinical trial for pancreatic cancer. The Company provides a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers including breast, lung, prostate, gastric, esophageal and pancreatic cancers.

Receive TYME News and Ratings via Email

Sign-up to receive the latest news and ratings for TYME and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TYME
CUSIPN/A
Phone646-205-1603

Debt

Debt-to-Equity RatioN/A
Current Ratio3.40%
Quick Ratio3.40%

Price-To-Earnings

Trailing P/E Ratio-20.5882352941176
Forward P/E Ratio-14.91
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.08 per share
Price / Book42.88

Profitability

Trailing EPS($0.17)
Net Income$-15,200,000.00
Net MarginsN/A
Return on Equity-219.60%
Return on Assets-152.87%

Miscellaneous

EmployeesN/A
Outstanding Shares90,900,000

Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions

What is Tyme Technologies' stock symbol?

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

Where is Tyme Technologies' stock going? Where will Tyme Technologies' stock price be in 2018?

3 analysts have issued twelve-month price targets for Tyme Technologies' stock. Their predictions range from $7.00 to $9.50. On average, they anticipate Tyme Technologies' stock price to reach $8.25 in the next year. View Analyst Ratings for Tyme Technologies.

Are investors shorting Tyme Technologies?

Tyme Technologies saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 924,724 shares, an increase of 39.2% from the January 12th total of 664,237 shares. Based on an average trading volume of 229,015 shares, the days-to-cover ratio is currently 4.0 days. Approximately 3.7% of the shares of the company are sold short.

Who are some of Tyme Technologies' key competitors?

Who owns Tyme Technologies stock?

Tyme Technologies' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.26%), Family Management Corp (0.12%), BlueCrest Capital Management Ltd (0.04%), Franklin Street Advisors Inc. NC (0.03%), Wells Fargo & Company MN (0.03%) and Monashee Investment Management LLC (0.02%). Company insiders that own Tyme Technologies stock include Michael Demurjian and Steve Hoffman. View Institutional Ownership Trends for Tyme Technologies.

Who bought Tyme Technologies stock? Who is buying Tyme Technologies stock?

Tyme Technologies' stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Family Management Corp, BlueCrest Capital Management Ltd, Franklin Street Advisors Inc. NC, Wells Fargo & Company MN and Monashee Investment Management LLC. View Insider Buying and Selling for Tyme Technologies.

How do I buy Tyme Technologies stock?

Shares of Tyme Technologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tyme Technologies' stock price today?

One share of Tyme Technologies stock can currently be purchased for approximately $3.43.

How big of a company is Tyme Technologies?

Tyme Technologies has a market capitalization of $318.16 million. The company earns $-15,200,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.

How can I contact Tyme Technologies?

Tyme Technologies' mailing address is 44 WALL STREET 12TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 646-205-1603 or via email at [email protected]


MarketBeat Community Rating for Tyme Technologies (TYME)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  18 (Vote Outperform)
Underperform Votes:  26 (Vote Underperform)
Total Votes:  44
MarketBeat's community ratings are surveys of what our community members think about Tyme Technologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Tyme Technologies (NASDAQ:TYME) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.25$7.50$7.00N/A
Price Target Upside: 94.58% upside14.85% upside88.17% upsideN/A

Tyme Technologies (NASDAQ:TYME) Consensus Price Target History

Price Target History for Tyme Technologies (NASDAQ:TYME)

Tyme Technologies (NASDAQ:TYME) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018HC WainwrightReiterated RatingBuy -> Buy$8.00 -> $9.50HighView Rating Details
1/3/2018Canaccord GenuityInitiated CoverageBuy -> BuyHighView Rating Details
11/17/2017Evercore ISIInitiated CoverageOutperform$7.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Tyme Technologies (NASDAQ:TYME) Earnings History and Estimates Chart

Earnings by Quarter for Tyme Technologies (NASDAQ:TYME)

Tyme Technologies (NASDAQ TYME) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q2 2018($0.06)ViewN/AView Earnings Details
8/10/2017Q1 2018($0.03)ViewN/AView Earnings Details
6/12/2017Q4 2017($0.04)ViewN/AView Earnings Details
2/14/2017Q3 2017($0.04)ViewN/AView Earnings Details
8/9/2016Q1 2017($0.07)ViewN/AView Earnings Details
5/10/2016Q4 2016($0.03)ViewN/AView Earnings Details
4/11/2016Q3 2016($0.03)ViewN/AView Earnings Details
11/23/2015Q2 2016($0.03)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Tyme Technologies (NASDAQ:TYME) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.23 EPS
Next Year EPS Consensus Estimate: $-0.39 EPS

Dividends

Dividend History for Tyme Technologies (NASDAQ:TYME)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Tyme Technologies (NASDAQ TYME) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 2.44%
Insider Trades by Quarter for Tyme Technologies (NASDAQ:TYME)
Institutional Ownership by Quarter for Tyme Technologies (NASDAQ:TYME)

Tyme Technologies (NASDAQ TYME) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2018Michael DemurjianCOOSell400$3.75$1,500.00View SEC Filing  
2/12/2018Steve HoffmanCEOSell17,986$3.82$68,706.52View SEC Filing  
12/11/2017Michael DemurjianCOOSell1,900$3.73$7,087.00View SEC Filing  
11/14/2017Michael DemurjianCOOSell50,000$3.34$167,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Tyme Technologies (NASDAQ TYME) News Headlines

Source:
DateHeadline
Critical Survey: Tyme Technologies (TYME) vs. Bioverativ (BIVV)Critical Survey: Tyme Technologies (TYME) vs. Bioverativ (BIVV)
www.americanbankingnews.com - February 18 at 7:04 PM
Zacks: Tyme Technologies Inc (TYME) Given Average Rating of "Strong Buy" by BrokeragesZacks: Tyme Technologies Inc (TYME) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - February 18 at 5:24 AM
Tyme Technologies (TYME) Downgraded by Zacks Investment ResearchTyme Technologies (TYME) Downgraded by Zacks Investment Research
www.americanbankingnews.com - February 15 at 2:44 PM
Insider Selling: Tyme Technologies Inc (TYME) CEO Sells 17,986 Shares of StockInsider Selling: Tyme Technologies Inc (TYME) CEO Sells 17,986 Shares of Stock
www.americanbankingnews.com - February 14 at 9:58 PM
Tyme to Present at RBC Capital Markets 2018 Global Healthcare ConferenceTyme to Present at RBC Capital Markets 2018 Global Healthcare Conference
finance.yahoo.com - February 13 at 8:36 AM
Tyme Technologies Inc (TYME) Expected to Post Earnings of -$0.06 Per ShareTyme Technologies Inc (TYME) Expected to Post Earnings of -$0.06 Per Share
www.americanbankingnews.com - February 11 at 7:08 PM
Tyme Technologies Inc (TYME) Short Interest UpdateTyme Technologies Inc (TYME) Short Interest Update
www.americanbankingnews.com - February 11 at 1:08 AM
BRIEF-Tyme Technologies Says To Report Full Phase II Data For SM-88 In Second Half Of 2018BRIEF-Tyme Technologies Says To Report Full Phase II Data For SM-88 In Second Half Of 2018
www.reuters.com - February 9 at 6:01 PM
Contrasting Tyme Technologies (TYME) & Its CompetitorsContrasting Tyme Technologies (TYME) & Its Competitors
www.americanbankingnews.com - February 9 at 10:12 AM
Tyme Provides Clinical and Corporate Update for Fiscal Third Quarter 2017Tyme Provides Clinical and Corporate Update for Fiscal Third Quarter 2017
finance.yahoo.com - February 8 at 9:26 AM
HC Wainwright Boosts Tyme Technologies (TYME) Price Target to $9.50HC Wainwright Boosts Tyme Technologies (TYME) Price Target to $9.50
www.americanbankingnews.com - February 8 at 7:16 AM
BidaskClub Downgrades Tyme Technologies (TYME) to Strong SellBidaskClub Downgrades Tyme Technologies (TYME) to Strong Sell
www.americanbankingnews.com - February 3 at 10:12 AM
 Tyme Technologies, Inc. (TYME) Receives Consensus Rating of "Strong Buy" from Analysts Tyme Technologies, Inc. (TYME) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - February 2 at 7:24 PM
Tyme Announces Prostate Cancer Collaboration with Dr. Mack Roach III of UCSFTyme Announces Prostate Cancer Collaboration with Dr. Mack Roach III of UCSF
finance.yahoo.com - January 30 at 8:50 AM
Tyme Technologies (TYME) Downgraded to "Sell" at BidaskClubTyme Technologies (TYME) Downgraded to "Sell" at BidaskClub
www.americanbankingnews.com - January 27 at 1:46 PM
Tyme Announces Positive Efficacy Data for SM-88 in Pancreatic Cancer at 2018 ASCO Gastrointestinal Cancers SymposiumTyme Announces Positive Efficacy Data for SM-88 in Pancreatic Cancer at 2018 ASCO Gastrointestinal Cancers Symposium
finance.yahoo.com - January 27 at 8:50 AM
Zacks: Analysts Anticipate Tyme Technologies, Inc. (TYME) to Post -$0.06 EPSZacks: Analysts Anticipate Tyme Technologies, Inc. (TYME) to Post -$0.06 EPS
www.americanbankingnews.com - January 25 at 7:10 PM
 Brokerages Set $8.33 Price Target for Tyme Technologies, Inc. (TYME) Brokerages Set $8.33 Price Target for Tyme Technologies, Inc. (TYME)
www.americanbankingnews.com - January 25 at 3:30 PM
Tyme Technologies (TYME) versus Lipocine (LPCN) Head to Head ComparisonTyme Technologies (TYME) versus Lipocine (LPCN) Head to Head Comparison
www.americanbankingnews.com - January 19 at 11:42 PM
Tyme Technologies (TYME) & Its Competitors Head to Head AnalysisTyme Technologies (TYME) & Its Competitors Head to Head Analysis
www.americanbankingnews.com - January 12 at 11:06 PM
 Tyme Technologies, Inc. (TYME) Given $8.33 Average Price Target by Analysts Tyme Technologies, Inc. (TYME) Given $8.33 Average Price Target by Analysts
www.americanbankingnews.com - January 10 at 1:44 AM
Zacks: Analysts Anticipate Tyme Technologies, Inc. (TYME) to Post -$0.06 Earnings Per ShareZacks: Analysts Anticipate Tyme Technologies, Inc. (TYME) to Post -$0.06 Earnings Per Share
www.americanbankingnews.com - January 8 at 5:06 PM
Tyme Announces Presentation of Clinical Data on SM-88 in Prostate Cancer at 2018 ASCO Genitourinary Cancers SymposiumTyme Announces Presentation of Clinical Data on SM-88 in Prostate Cancer at 2018 ASCO Genitourinary Cancers Symposium
finance.yahoo.com - January 4 at 8:27 AM
Tyme to Present at 36th Annual J.P. Morgan Healthcare ConferenceTyme to Present at 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 11:19 AM
Tyme Technologies, Inc. (TYME)Tyme Technologies, Inc. (TYME)
finance.yahoo.com - December 19 at 6:17 PM
Tyme Inc. (TYME) to Present Efficacy Data on SM-88 in Pancreatic Cancer at 2018 ASCO Gastrointestinal Cancers SymposiumTyme Inc. (TYME) to Present Efficacy Data on SM-88 in Pancreatic Cancer at 2018 ASCO Gastrointestinal Cancers Symposium
www.streetinsider.com - December 19 at 6:17 PM
Tyme to Present Efficacy Data on SM-88 in Pancreatic Cancer at 2018 ASCO Gastrointestinal Cancers SymposiumTyme to Present Efficacy Data on SM-88 in Pancreatic Cancer at 2018 ASCO Gastrointestinal Cancers Symposium
finance.yahoo.com - December 19 at 8:25 AM
Tyme Technologies (TYME) Receives New Coverage from Analysts at HC WainwrightTyme Technologies (TYME) Receives New Coverage from Analysts at HC Wainwright
www.americanbankingnews.com - December 15 at 10:40 AM
Tyme to Present at Biotech Showcase™ 2018Tyme to Present at Biotech Showcase™ 2018
finance.yahoo.com - December 13 at 6:32 PM
Tyme Provides Update on At-The-Market Financing ActivityTyme Provides Update on At-The-Market Financing Activity
finance.yahoo.com - December 5 at 8:42 AM
Pre-Open Stock Movers 11/17: (HIBB) (TYME) (ANF) (SPLK) Higher; (VBLT) (CNTY) (VERI) Lower (more...)Pre-Open Stock Movers 11/17: (HIBB) (TYME) (ANF) (SPLK) Higher; (VBLT) (CNTY) (VERI) Lower (more...)
www.streetinsider.com - November 19 at 10:06 AM
Tyme Technologies, Inc. (TYME) Research Coverage Started at Evercore ISITyme Technologies, Inc. (TYME) Research Coverage Started at Evercore ISI
www.americanbankingnews.com - November 17 at 8:32 PM
Tyme Technologies, Inc. (TYME) COO Sells $167,000.00 in StockTyme Technologies, Inc. (TYME) COO Sells $167,000.00 in Stock
www.americanbankingnews.com - November 16 at 8:37 PM
Tyme to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive ConferenceTyme to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
finance.yahoo.com - November 14 at 12:49 PM

SEC Filings

Tyme Technologies (NASDAQ:TYME) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Tyme Technologies (NASDAQ:TYME) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Tyme Technologies (NASDAQ TYME) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.